Obesity News

WEST PALM BEACH, Fla. — Obesity was strongly associated with disability worsening, disease progression and declining quality of life in a cohort of adults diagnosed with multiple sclerosis, according to a presenter at ACTRIMS 2024.

Tirzepatide and injectable semaglutide were associated with the greatest weight loss after a year of treatment among several GLP-1 receptor agonists, a recent study showed.

Excess body weight may be a key risk factor for the development of early-onset colorectal cancer, according to research published in International Journal of Cancer.

Medicare Part D plans can begin to cover semaglutide to lower risk for cardiovascular events among adults with overweight or obesity and preexisting CVD, according to new guidance from the Centers of Medicare & Medicaid Services.

Girls with obesity or overweight were more likely to see their general practitioner for a musculoskeletal consultation, according to a study published in Archives of Disease in Childhood.

An online obesity treatment and maintenance program resulted in significant weight loss among primary care patients, according to findings from a randomized study published in JAMA Internal Medicine.

Along with type 2 diabetes, dyslipidemia and thrombosis, the cardiometabolic diseases of obesity, hypertension and heart disease form a complex triad that poses significant risks to the health of individuals.

People living in extreme poverty had a higher prevalence of heart disease risk factors such as hypertension, diabetes, smoking, obesity and dyslipidemia than previously thought, according to an analysis of people from 78 countries.

Around 4% of adolescents in the United States meet the AAP’s eligibility criteria for metabolic and bariatric surgery, according to findings published in Pediatrics.

Novo Nordisk and the FDA announced approval of a new indication for semaglutide 2.4 mg for reduction of risk for major adverse cardiovascular events in adults with overweight or obesity and established CVD.